Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles.
-
Ronchi A, Vitiello P, D'Abbronzo G, Caccavale S, Argenziano G, Sica A, Alfano R, Savarese G, Berretta M, Cozzolino I, Franco R. Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review. Int J Mol Sci. 2023 Mar 25; 24(7).
-
Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Althoff KN, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas. Blood Adv. 2022 03 08; 6(5):1420-1431.
-
Young LA, O'Connor LO, de Renty C, Veldman-Jones MH, Dorval T, Wilson Z, Jones DR, Lawson D, Odedra R, Maya-Mendoza A, Reimer C, Bartek J, Lau A, O'Connor MJ. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Res. 2019 07 15; 79(14):3762-3775.
-
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019 04; 33(2):98-110.
-
Brach D, Johnston-Blackwell D, Drew A, Lingaraj T, Motwani V, Warholic NM, Feldman I, Plescia C, Smith JJ, Copeland RA, Keilhack H, Chan-Penebre E, Knutson SK, Ribich SA, Raimondi A, Thomenius MJ. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL. Mol Cancer Ther. 2017 11; 16(11):2586-2597.
-
Beheshti A, Vanderburg C, McDonald JT, Ramkumar C, Kadungure T, Zhang H, Gartenhaus RB, Evens AM. A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. PLoS One. 2017; 12(1):e0170521.
-
Lee WJ, Won KH, Won CH, Chang SE, Choi JH, Moon KC, Park CS, Huh J, Suh C, Lee MW. Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type. Acta Derm Venereol. 2016 Feb; 96(2):245-50.
-
Coleman M, Lammers PE, Ciceri F, Jacobs IA. Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):175-81.
-
Ramachandiran S, Adon A, Guo X, Wang Y, Wang H, Chen Z, Kowalski J, Sunay UR, Young AN, Brown T, Mar JC, Du Y, Fu H, Mann KP, Natkunam Y, Boise LH, Saavedra HI, Lossos IS, Bernal-Mizrachi L. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-?B pathway. Int J Cancer. 2015 May 15; 136(10):2341-51.
-
Yang JH, Choi SJ, Won CH, Chang S, Lee MW, Huh JR, Lee KH, Choi JH, Moon KC. Paraneoplastic erythroderma: an unusual manifestation of diffuse large B-cell lymphoma. Int J Dermatol. 2013 Sep; 52(9):1149-51.